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Aims To provide insight into the mechanism of sudden adult death syndrome (SADS) and to give new clinical guidelines for
the cardiac management of patients with the most commonmitochondrial DNAmutation, m.3243A.G. These studies
were initiated after two young, asymptomatic adults harbouring the m.3243A.G mutation died suddenly and unex-
pectedly. The m.3243A.G mutation is present in 1 in 400 of the population, although the recognized incidence of
mitochondrial DNA (mtDNA) disease is 1 in 5000.
Methods
and results
Pathological studies including histochemistry and molecular genetic analyses performed on various post-mortem sam-
ples including cardiac tissues (atrium and ventricles) showed marked respiratory chain deficiency and high levels of the
m.3243A.G mutation. Systematic review of cause of death in our m.3243A.G patient cohort showed the person-
time incidence rate of sudden adult death is 2.4 per 1000 person-years. A further six cases of sudden death among
extended family members have been identified from interrogation of family pedigrees.
Conclusion Our findings suggest that SADS is an important cause of death in patients with m.3243A.G and likely to be due to
widespread respiratory chain deficiency in cardiac muscle. The involvement of asymptomatic relatives highlights the
importance of family tracing in patients with m.3243A.G and the need for specific cardiac arrhythmia surveillance
in the management of this common genetic disease. In addition, these findings have prompted the derivation of cardiac
guidelines specific to patients with m.3243A.G-related mitochondrial disease. Finally, due to the prevalence of this
mtDNA point mutation, we recommend inclusion of testing for m.3243A.G mutations in the genetic autopsy of
all unexplained cases of SADS.
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Translational perspective
We report striking respiratory chain deficiency and high levels of the m.3243A.G mitochondrial DNA mutation in cardiac muscle from
two young asymptomatic adults found dead-in-bed. Our findings suggest this is an unrecognized clinical entity in individuals carrying the
m.3243A.G mutation. We have developed new cardiac guidelines for the management of patients with the m.3243A.G mutation.
In addition, because of the frequency of this mutation in the population, it should be screened for in all cases of unexplained SADS.
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Introduction
Mitochondrial disorders are a common cause of inherited disease,
exhibiting marked phenotypic and genotypic heterogeneity. The
most common form of mitochondria disease is due to the pathogen-
ic mitochondrial DNA (mtDNA) point mutation m.3243A.G in
the mt-tRNA leucine gene (MTTL-1). The prevalence of this muta-
tion in the population is 1 in 400,1,2 although the reported inci-
dence of clinically manifesting disease due to the mutation ranges
from 3.5 to 16.3 per 100 000 in the adult population.3,4
The phenotypes associated with the m.3243A.G mutation in-
clude clinical syndromes such as mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes (MELAS),5 chronic progres-
sive external ophthalmoplegia (CPEO),6 and maternally inherited
deafness and diabetes (MIDD),7 though the majority of patients
have clinical features that do not fit any of these classifications.8 Car-
diac muscle involvement, frequently manifesting as hypertrophic
cardiomyopathy (HCM), may occur in up to 40% of patients with
m.3243A.G-related mitochondrial disease9 and is recognized as
an independent predictor of morbidity and early mortality in these
patients.10,11
The m.3243A.G mutation is invariably heteroplasmic with a
mixture of mutated and wild-type mtDNA present in patients.
Many patients with high levels of the heteroplasmic m.3243A.G
mutation have progressive, disabling disease leading to early death,
while individuals with low level m.3243A.G may never develop
symptoms. Previous reports of mortality in patients with
m.3243A.G mutation predominantly include those symptomatic
individuals with chronic and severe disease burden. The most com-
mon causes of death include cardiac events;12 status epilepticus,
stroke-like episodes; aspiration pneumonia or sepsis; paralytic ileus
and metabolic acidosis.13,14
This study was initiated by the death of two young, asymptomatic
m.3243A.G adults who died suddenly and unexpectedly. We be-
lieve that these cases represent an important unrecognized clinical
entity of m.3243A.G disease. We sought to determine the likely
mechanism of the sudden death and the incidence of sudden adult
death syndrome (SADS) over the last 5 years in patients known to
harbour the m.3243A.GmtDNA point mutation and develop new
clincial guidelines to minimize cardiac risk associated with having this
mutation.
Methods
Index case reports
Case 1
A 30-year-old man was assessed clinically following pedigree tracing of
m.3243A.G disease. His mother presented with MELAS at the age of
54 and was found to harbour high levels of the m.3243A.G mutation
(66% in skeletal muscle, 53% in urine, and 20% in blood). The young man
was well, worked full time, and was undertaking regular exercise, includ-
ing both resistance and endurance training. He was asymptomatic but,
on specific questioning, admitted to mild hearing difficulty and occasion-
al mild symptoms similar to irritable bowel syndrome. His routine car-
diac investigations including resting 12-lead electrocardiogram (ECG),
24-h ambulatory ECG monitoring, and echocardiography revealed no
abnormalities. Magnetic resonance imaging (MRI) brain revealed mild
cerebellar atrophy, although neurological examination was normal.
Genetic investigations showed 92 and 39% m.3243A.G mutation
load in urine and blood, respectively. He had been socializing with
friends the night before his death and had consumed 10 units of alcohol.
He was found dead-in-bed the following morning.
Case 2
A 33-year-old woman was originally identified on pedigree tracing as a
member of a family with m.3243A.G disease. Her sister presented in
her teens with multiple stroke-like episodes compatible with MELAS
and had high levels of m.3243A.G mutation. Her mother and another
sister are asymptomatic (m.3243A.G heteroplasmy levels not avail-
able). The patient worked full time as a teacher and lived an active
life, including going to a gym on a regular basis. She was found to have
a normal resting 12-lead ECG and only mild, non-progressive left ven-
tricular hypertrophy (LVH) detected on regular surveillance echocardi-
ography. She reported no cardiorespiratory symptoms. She was taking
regular food supplements including Co-enzyme Q10, B-Complex vita-
mins, and probiotics only. Her m.3243A.G mutation load was 68%
in urine and 30% in blood. She was found dead-in-bed at home following
a night out with friends.
Post-mortem muscle histology and histochemistry
Standard histological and histochemical analyseswere performed on fresh
frozen 10 mm cryosections from various post-mortem samples including
cardiac tissues (atrium and ventricles), skeletal muscle, liver, and kidney.
Standard methods included sequential cytochrome c oxidase (COX)/
succinate dehydrogenase (SDH) histochemistry to assay both Complex
IV (COX) and Complex II (SDH) activities.15 Sequential COX/SDH
histochemistry was performed on frozen 15-mm tissue sections as previ-
ously described.16 Neuropathological staining and immunohistochemistry
was performed on 5 mm sections as previously described.17
Molecular genetic studies
Total DNAwas extracted from several tissues (Table 1; see Supplemen-
tary material online, Table S1) by standard procedures. Pyrosequencing
was used to quantify the m.3243G.A heteroplasmy levels.20
Cause of death in m.3243A>G patients
consented to MRC cohort in Newcastle
Patients identified as harbouring the m.3243A.G mtDNA point muta-
tion and who consented to the Medical Research Council (MRC) Cen-
tre Mitochondrial Disease Patient Cohort were identified. We also
obtained detailed family histories of those included in the cohort. Cause
of death over the last 5 years (April 2009 to October 2014 inclusive)
was reviewed and annual incidence-based mortality was calculated.
Clinical investigations were performed according to the Declaration
of Helsinki. Local study approval was granted (NRES Committee North
East- Newcastle & North Tyneside 2) and written informed consent
from both patients’ families was obtained prior to study inclusion.
COX (proportional hazards) regression
analysis for the development of
cardiomyopathy in patients with m.3243A>G
mutation
For patients with mitochondrial disease, the dominant cardiac manifest-
ation we have seen is increased LV-wall thickness. This is probably
caused by an abnormal, primitive response to energy imbalance in the
heart. To define hypertrophy, we have used the standard echo normal
range values (defined as diastolic, interventricular septal thickness, and/or
diastolic, posterior wall thickness .1.2 cm on 2D transthoracic
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echocardiography as per British Society of Echocardiography guidelines
to distinguish normal from abnormal) and then described as to whether
the pattern of hypertrophy seen was septal only or concentric (global).
The association of putative factors for the development of cardiomyop-
athy (gender and heteroplasmy measured in blood, urinary sediment,
and skeletal muscle) were investigated by Cox regression21 using
PROC PHREG in SAS 9.2 (Cary, NC, USA). Statistical significance was
determined at P, 0.05.
Results
Histology and histochemical findings
Drug toxicology screen was negative for both Case 1 and 2, while
low level of alcohol (63 mg/dL) was detected in Case 1. There
was no gross structural cardiac abnormality found in Case 1, and
there was only mild left ventricular hypertrophy identified in Case
2. The cause of death could not be determined for either case at ini-
tial autopsy. The autopsy findings, tissue morphology, histochemis-
try, and heteroplasmy level of both cases are summarized in Table 1
and see Supplementary material online, Table S1. Histochemical ana-
lyses of cardiac tissue showed high levels of COX deficiency in both
cases (Figure 1). There was additional patchy but prominent cyto-
plasmic vacuolation and enlargement of cardiomyocytes in Case
2’s left ventricle. There was limited evidence of CNS involvement
in either case with neuronal population density intact with an ab-
sence of astrogliosis and ischaemic lesions, although some evidence
of respiratory chain deficiency particularly in blood vessels.
Levels of heteroplasmy of m.3243A>G
mutation in tissues
The level of m.3243A.Gwas high in all examined tissues fromCase
1 with over 90% in several cardiac tissues. There was also high level
of m.3243A.G in brain, liver, and adrenal glands. In Case 2, levels of
m.3243A.Gwere also high in multiple tissues including heart mus-
cle and brain (see Supplementary material online, Table S1).
Cause of death in m.3243A>G patients
consented to MRC cohort Newcastle
We included 209 patients with the m.3243A.G mutation; there
were 14 deaths documented over the preceeding 6 years (April
2009 to October 2014 inclusive) (Table 2). We estimate that the
incidence rate of all-cause mortality for m.3243A.G patients is
17 per 1000 person-years (95% CI 9.1–28) and the incidence rate
of SADS is 2.4 per 1000 person-years (95% CI 0.29–8.6)(see
Supplementary material online, Table S2). Interrogation of family
pedigrees of these 209 patients (90 pedigrees) identified a further
6 adults (18–44 years) who were clinically asymptomatic or mildly
affected but presumed obligate carriers, as having died suddenly and
unexpectedly (prior to the establishment of the MRC cohort), sug-
gesting that SADS is not uncommon but perhaps, until now, an un-
recognized clinical entity in young, asymptomatic adults with
m.3243A.G disease.
Identifying associated factors for
development of cardiomyopathy in
patients with m.3243A>G mutation
Median survival time to the development of cardiomyopathy for all
patients is 67.6 years. Using Cox regression, we identified that the
most explanatory factors for the development of cardiomyopathy
are blood heteroplasmy (P, 0.0001) and gender (P ¼ 0.0143)
(n ¼ 164), with men significantly at greater risk for the development
of cardiomyopathy (for details, see Supplementary material online,
Table S3). Survival functions using blood heteroplasmy and gender
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 A summary of the morphological, histochemical, and molecular genetic findings in cardiac tissue of Cases 1 and 2
Case 1 Case 2
Body weight (kg) 66 58
Height (m) 1.66 1.63
Autopsy interval (h) 187 96
Toxicology Negative for illicit drugs
Blood ethanol content 63 mg/dL
Negative for illicit drugs and ethanol
Cardiovascular system
Heart weight (g); Reference: male 360+75;
female 308+79
325 365
Gross appearance Normal Mild LVH; minimal subendocardial fibrosis of the left
ventricular outflow tract
Histopathological findings Normal Patchy but prominent cytoplasmic vacuolation and
enlargement of cardiac myocytes seen in left ventricle
Histochemistry 40–60% COX deficiency in both
ventricles and interventricular septum
15–20% COX deficiency in both ventricles
m.3243A.G Heteroplasmy (%) Left ventricle: 91
Right ventricle: 95
Interventricular septum: 92
Both atria: 93
Left ventricle: 76
Right ventricle: 78
The reference range of organ weight is based on the findings from these reports.18,19
COX, cytochrome c oxidase; RRF, ragged red fibres; LVH, left ventricular hypertrophy; h, hours.
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are shown in Figure 2 and demonstrate a male predilection to earlier
onset of cardiomyopathy (P ¼ 0.0143). These data have facilitated
the development of a simple, on-line tool for plotting the prediction
of the development of cardiomyopathy for a given heteroplasmy
and gender (http://research.ncl.ac.uk/mitoresearch/cardio/).
Discussion
We believe these two patients presenting with SADS highlight an
important and unrecognized phenotype in those who carry the
m.3243A.G mutation. There are several striking similarities be-
tween the cases: (i) they were only identified as carrying the
m.3243A.Gmutation via family screening and were asymptomatic;
(ii) they had high mutation load in both urine and blood; (iii) there
was extensive evidence of respiratory chain deficiency in multiple
organs and especially in heart; (iv) at least one of their immediate
family members clinically manifested with the severe MELAS
phenotype; (v) both were last seen in good health within 12 h of
their sudden death.
Our centre’s experience of all-cause mortality in patients with
m.3243A.G disease is similar to that reported by other groups.
However, sudden death in patients with m. 3243A.G mutation
is rarely reported in the literature, and it appears to occur among
those with severe disease, and identifiable risk factors including
cardiomyopathy, diabetes, and epilepsy, that could plausibly have
contributed to their deaths.11,14 These unexpected deaths in
our patients suggests that SADS can occur without identifiable
risk factors11; as in Case 1, and across the entire spectrum of
m.3243A.G disease, from asymptomatic to severely affected
individuals.
Given the circumstances and lack of any prodrome, the likely
cause of sudden death in our patients is a cardiac arrhythmia.
Cardiac abnormalities are the main cause of sudden death in young
adults. HCM is common in patients harbouring the m.3243A.G
Figure 1 Evidence of mitochondrial dysfunction in skeletal and cardiac muscles by cytochrome c oxidase/succinate dehydrogenase histochem-
istry. To measure cytochrome c oxidase/succinate dehydrogenase enzyme activity, sequential cytochrome c oxidase/succinate dehydrogenase
histochemistry was performed on post-mortem skeletal (quadriceps) and cardiac (right and left ventricle) muscle sections from patients and a
control. Cells that are identified by a brown reaction product have functional cytochrome c oxidase and succinate dehydrogenase activity; those
that are blue have lost cytochrome c oxidase activity but retain succinate dehydrogenase activity. This assay reveals a mosaic pattern of variable
cytochrome c oxidase-deficiency (blue cells) within all patients’ tissues (Case 1 and 2), while control tissues (Control) reveal functional cyto-
chrome c oxidase and succinate dehydrogenase activities (brown cells). Scale bar ¼ 50 mm.
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mutation.22 In addition, cardiac arrhythmias have also been
described frequently in patients with m.3243A.G including
Wolff–Parkinson–White syndrome, supraventricular tachycardia,
atrial fibrillation, and depolarization abnormalities.12,23,24 Cardiac
fibre disarray that has been shown to underlie ventricular tachyar-
rhythmias in some forms of HCM25,26 was not evident in our two
cases. Case 1 had a normal resting ECG, echocardiogram, and
24-h ECG monitoring. His autopsy did not reveal any gross
structural cardiac abnormality. Case 2 had documented mild LVH;
however, the extent of left ventricular wall thickness index would
not have suggested an increased risk of sudden cardiac death.27 Per-
haps most surprising was the lack of cardiac manifestations consid-
ering the severity of the biochemical defect found in cardiomyocytes
of both patients. Though neither patient had consumed large
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Cause of death in patients harbouring the m.3243A>G mutation in Newcastle from April 2009 to October 2014
No Sex Deceased age Heteroplasmy NMDAS score Cause of death
Mu (%) U (%) B (%)
1 M 48 55 13 19 Coronary artery diseasea
2 F 65 62 60 17 62 HCM
3 M 12 82 46 N/P HCM and renal failure
4 M 58 70 N/P Not availablea
5 M 60 33 7 50 Aspiration pneumonia secondary to bowel pseudo-obstruction
6 F 61 45 7 0 Metastatic breast cancera
7 M 20 93 66 19 Cardiorespiratory failure (HCM)
8 M 23 93 61 67 Multi-organ failure
9 M 33 90 3 65 End-stage MELAS
10 F 53 91 49 Severe encephalopathy secondary to urinary tract infection
11 F 66 39 55 6 60 Aspiration pneumonia secondary to bowel pseudo-obstruction
12 M 52 75 29 42 HCM and pneumonia
13 F 33 90 68 30 4 SADSb
14 M 30 85 53 20 4 SADSb
The mean deceased age is 43.5 years with 95% CI (33.2–53.8).
M, male; F, female; Mu, muscle; U, urine; B, blood; NMDAS, Newcastle Mitochondrial Disease Adult Scale; HCM, hypertrophic cardiomyopathy; MELAS, mitochondrial
encephalomyopathy, lactic acidosis and stroke-like episode; SADS, sudden adult death syndrome.
aUnrelated to mitochondrial disease.
bTwo index cases of this report.
Figure 2 Normal cardiac function survival probability according to gender and blood heteroplasmy. (A) Normal cardiac function survival prob-
ability (survival function) for males (blue) and females (red). Censored data (i.e. patients who have not developed cardiomyopathy at their most
recent clinical assessment) are shown as crosses, normal cardiac functions are shown as solid lines with 95% confidence intervals. The age for
developing cardiomyopathy in males is significantly younger than females (P ¼ 0.0143). (B) Normal cardiac function survival probability (survival
function) for males (blue) and females (red) with varying levels of blood heteroplasmy (10% dotted lines, 30% dashed lines, 50% solid lines).
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amounts of alcohol, or appeared unwell to their friends, extreme
sensitivity to alcohol has previously been reported in patients
with respiratory chain disease.28 A potential theoretical risk is that
lactic acidosis caused by the combined effect of the underlying car-
diac respiratory chain defect, with the inhibitory effects of alcohol
on gluconeogenesis,29 may have triggered a fatal cardiac arrhythmia
and would advise caution in the use of alcohol in this group of
patients. However, given that many of these patients develop lactic
acidosis without suffering from cardiac arrhythmias, we believe that
further work on this aspect is required.
Death related to seizures is also a possibility. Seizure-induced
central hypoventilation, cardiac arrhythmia, or abnormal autonomic
response have been proposed as possible mechanisms in sudden un-
explained death in epilepsy (SUDEP).30 However, neither patient
had a history of epilepsy, and brain structure was intact at autopsy,
though it did show evidence of respiratory-deficient neurons and
blood vessels. Whether this makes the patients more vulnerable
to seizures and sudden death is not known.
It is also possible that the deaths are unrelated to the m.3243A.G
mutation, though no other cause of death was identified at autopsy.
Sudden death in young adults is very rare and the incidence ranges
from 1 to 3.73 per 100 000.31–34 The majority of these deaths have
a cardiac aetiology with up to 70% having structurally abnormal hearts
at autopsy.33,35
These cases highlight again the challenges of developing cardiac
care pathways for patients with m.3243A.Gmutation. The recently
devised tool (HCM Risk-SCD)36 to predict sudden death in HCM,
unfortunately would not have identified either of our patients at
risk of sudden death, emphasizing the complexity of these metabolic
disorders. Based on these guidelines, the data presented, and our
centre’s clinical experience, we propose the following Expert Opin-
ion Guidelines (summarized in Figure 3):
(1) Patients with ≥15 mm left ventricular wall thickness index
on echocardiogram27 and/or evidence of a pre-excitation
syndrome on ECG and/or family history of sudden adult death
syndrome should be made aware of the risk of sudden death
and the importance of regular health surveillance.37
(2) All individuals who harbour the m.3243A.G mutation should
have a cardiovascular risk assessment.We advise implementation
of the prediction tool to stratify individual risk of cardiomyopathy
development in patients with m.3243A.G-related mitochon-
drial disease (http://research.ncl.ac.uk/mitoresearch/cardio/).
High-risk individuals are defined as those having normal cardiac
Figure 3 Summary flow diagram of cardiac risk assessment and management of patients harbouring the m.3243A.G mutation.
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function survival probability of 95% or lower for a given blood
heteroplasmy and gender and should be offered cardiac magnetic
resonance (CMR) to better define the presence of and/or degree
of LVHmore accurately.37,38 Early introduction of a combination
of angiotensin-converting enzyme inhibitor (ACE-I) and
b-blocker for those with confirmed cardiomyopathy is advo-
cated routinely by our centre, based on best practice cardiac
guidelines.39
(3) Cardiac electrophysiology testing is advisable for those with
overt or suspected pre-excitation syndromes (e.g. WPW syn-
drome) or AV-conduction abnormalities (e.g. prolonged PR
interval or prolonged QRS duration), particularly in those
with palpitations or unexplained episode/s of collapse. We
now also recommend implantation of a ECG loop recorder
to provide longer term surveillance of arrhythmias in patients
at high risk determined on blood heteroplasmy and age (see
above) and/or ≥15 mm left ventricular wall thickness index
on echocardiogram. Accessory pathways capable of sustaining
arrhythmias and those with short antegrade refractory periods
should undergo catheter ablation. Those confirmed to have
episodes of non-sustained ventricular tachycardia on loop-
recorder surveillance should be considered for a cardio-
verter-defibrillator.37,39 Those with confirmed pathological
bradycardia due to either sinus or AV-nodal conduction delay
can be considered for pacemaker fitting.
(4) Patients harbouring the m.3243.G mutation and with docu-
mented epilepsy should be advised of the inherent risk of
SUDEP.
(5) There should be extensive family tracing and genetic testing of-
fered to the relatives of patients with m.3243A.G since even
asymptomatic family members are at risk of sudden death.
We acknowledge that there are inherent limitations with aspects
of these guidelines, namely:
(1) Several aspects of our proposed guidelines (points 1 and 2) as
markers of SAD risk are made based upon extrapolation from
HCM. To date, we do not know whether identical limits apply
in m.3243A.G-related mitochondrial disease; aspects that
require further elucidation.
(2) Although these are expert opinion guidelines from a single cen-
tre, we are a nationally commissioned multispecialty and multi-
disciplinary service, charged with the care of patients with
mitochondrial disease from throughout the UK, exemplified
by our patient cohort of over 700 patients, which is the part
of the largest cohort worldwide. Combined with over 25 years’
experience in this field, this places us in a unique position to
devise such guidelines.
(3) Lastly, the incidence of cardiomyopathy on echocardiogram
maybe an under estimation of the true incidence of cardiac
involvement as we have previously shown.38
In conclusion, we report findings from two asymptomatic, young
adults with high levels of the m.3243A.G mutation who died sud-
denly and unexpectedly. The autopsy findings strongly point to an
arrhythmia mechanism of death. Combined with an annual inci-
dence of 2.4 per 1000 person-years, these findings suggest that
SADS is not uncommon. Most importantly, it is an unrecognized
clinical entity in young, asymptomatic adults with m.3243A.G dis-
ease. This suggests the need for increased vigilance in the cardiac
monitoring of even apparently asymptomatic individuals with the
m.3243A.G mutation. More detailed investigation and increased
deployment of implantable ECG loop recorders are justified by
the need to develop better predictors of arrhythmia risk.
In light of our findings, we recommend comprehensive family tra-
cing to screen for mitochondrial disease and where possible, histo-
chemical and/or molecular testing in all index cases of SADS.
Relatively simple additional investigations on autopsy samples would
screen for the m.3243A.G mutation and for abnormal respiratory
chain function in cardiac and skeletal muscle using COX/SDH
histochemistry.
Supplementary material
Supplementary material is available at European Heart Journal online.
Acknowledgements
We are extremely grateful to the families of our patients for their
help and to the MRC Centre Mitochondrial Disease Patient Cohort:
A Natural History Study and Patient Registry (REC reference num-
ber: 13/NE/0326) for data provision.
Funding
This work was supported by The Wellcome Trust (074454/Z/04/Z,
http://www.newcastle-mitochondria.com/), Newcastle University Cen-
tre for Ageing and Vitality (supported by the Biotechnology and Bio-
logical Sciences Research Council and Medical Research Council
[M501700]), UK NIHR Biomedical Research Centre for Ageing and
Age-related disease award to the Newcastle upon Tyne Hospitals
NHS Foundation Trust, Lily Foundation and the UK NHS Specialist
Commissioners which funds the ‘Rare Mitochondrial Disorders of
Adults and Children’ Diagnostic Service in Newcastle upon Tyne. This
work also received infrastructure support from the Newcastle NIHR
Biomedical Research Centre, Newcastle and North Tyneside Compre-
hensive Local Research Network. Funding to pay the Open Access pub-
lication charges for this article was provided by the Wellcome Trust
Centre 096919/Z/11/Z.
Conflict of interest: none declared.
References
1. Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic mitochon-
drial DNA mutations are common in the general population. Am J Hum Genet
2008;83:254–260.
2. Manwaring N, Jones MM, Wang JJ, Rochtchina E, Howard C, Mitchell P, Sue CM.
Population prevalence of the MELAS A3243G mutation. Mitochondrion 2007;7:
230–233.
3. Majamaa K, Moilanen JS, Uimonen S, Remes AM, Salmela PI, Karppa M,
Majamaa-Voltti KA, Rusanen H, Sorri M, Peuhkurinen KJ, Hassinen IE. Epidemiology
of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis,
and strokelike episodes: prevalence of the mutation in an adult population. Ameri-
can Journal of Human Genetics 1998;63:447–454.
4. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C,
Horvath R, Yu-Wai-Man P, Chinnery PF, Taylor RW, Turnbull DM, McFarland R.
Prevalence of nuclear and mitochondrial DNA mutations related to adult mito-
chondrial disease. Ann Neurol 2015;77:753–759.
5. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial my-
opathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical
syndrome. Ann Neurol 1984;16:481–488.
6. Moraes CT, Ciacci F, Silvestri G, Shanske S, Sciacco M, Hirano M, Schon EA,
Bonilla E, DiMauro S. Atypical clinical presentations associated with the MELAS
Sudden adult death syndrome and m.3243A.G Page 7 of 8
by guest on July 20, 2015
D
ow
nloaded from
 
mutation at position 3243 of human mitochondrial DNA. Neuromuscul Disord 1993;
3:43–50.
7. Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and
management of maternally inherited diabetes and deafness (MIDD) associated with
the 3243A.G mitochondrial point mutation. Diabet Med 2008;25:383–399.
8. Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE,
Rahman S, Hanna MG, McFarland R. The UK MRC Mitochondrial Disease Patient
Cohort Study: clinical phenotypes associated with the m.3243A.G mutation—
implications for diagnosis and management. J Neurol Neurosurg Psychiatry 2013;84:
936–938.
9. Bates MGD, Newman JH, Jakovljevic DG, Hollingsworth KG, Alston CL,
Zalewski P, Klawe JJ, Blamire AM, MacGowan GA, Keavney BD, Bourke JP,
Schaefer A, McFarland R, Newton JL, Turnbull DM, Taylor RW, Trenell MI,
Gorman GS. Defining cardiac adaptations and safety of endurance training in pa-
tients with m.3243A.G-related mitochondrial disease. Int J Cardiol 2013;168:
3599–3608.
10. Holmgren D, Wa˚hlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. Cardio-
myopathy in children with mitochondrial disease: clinical course and cardiological
findings. Eur Heart J 2003;24:280–288.
11. Majamaa-Voltti K, Turkka J, Kortelainen ML, Huikuri H, Majamaa K. Causes of death
in pedigrees with the 3243A.G mutation in mitochondrial DNA. J Neurol Neuro-
surg Psychiatry 2008;79:209–211.
12. Malfatti E, Laforet P, Jardel C, Stojkovic T, Behin A, Eymard B, Lombes A,
Benmalek A, Becane HM, Berber N, Meune C, Duboc D, Wahbi K. High risk of se-
vere cardiac adverse events in patients with mitochondrial m.3243A.Gmutation.
Neurology 2013;80:100–105.
13. Klopstock TM, Jaksch MM, Gasser TM. Age and cause of death in mitochondrial
diseases. Neurology 1999;53:855–857.
14. Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, Battista V,
Koenigsberger DY, Pascual JM, Shanske S, Sano M, Mao X, Hirano M,
Shungu DC, Dimauro S, De Vivo DC. Natural history of MELAS associated with
mitochondrial DNA m.3243A.G genotype. Neurology 2011;77:1965–1971.
15. Old SL, Johnson MA. Methods of microphotometric assay of succinate dehydro-
genase and cytochrome c oxidase activities for use on human skeletal muscle. His-
tochem J 1989;21:545–555.
16. Betts J, Jaros E, Perry RH, Schaefer AM, Taylor RW, Abdel-All Z, Lightowlers RN,
Turnbull DM. Molecular neuropathology of MELAS: level of heteroplasmy in indi-
vidual neurones and evidence of extensive vascular involvement. Neuropathol Appl
Neurobiol 2006;32:359–373.
17. Lax NZ, Whittaker RG, Hepplewhite PD, Reeve AK, Blakely EL, Jaros E, Ince PG,
Taylor RW, Fawcett PR, Turnbull DM. Sensory neuronopathy in patients harbour-
ing recessive polymerase gamma mutations. Brain 2012;135(Pt 1):62–71.
18. de la Grandmaison GL, Clairand I, Durigon M. Organ weight in 684 adult autopsies:
new tables for a Caucasoid population. Forensic Sci Int 2001;119:149–154.
19. Dekaban AS, Sadowsky D. Changes in brain weights during the span of human life:
relation of brain weights to body heights and body weights. Ann Neurol 1978;4:
345–356.
20. Alston CL, He L, Morris AA, Hughes I, de Goede C, Turnbull DM, McFarland R,
Taylor RW. Maternally inherited mitochondrial DNA disease in consanguineous
families. Eur J Hum Genet 2011;19:1226–1229.
21. CoxDR. Regression Models and Life-Tables. J R Stat Soc Ser B (Methodological) 1972;
34:187–220.
22. Bates MG, Bourke JP, Giordano C, d’Amati G, Turnbull DM, Taylor RW. Cardiac
involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and man-
agement. Eur Heart J 2012;33:3023–3033.
23. Okajima Y, Tanabe Y, Takayanagi M, Aotsuka H. A follow up study of myocardial
involvement in patients with mitochondrial encephalomyopathy, lactic acidosis,
and stroke-like episodes (MELAS). Heart 1998;80:292–295.
24. Majamaa-Voltti K, Peuhkurinen K, Kortelainen M-L, Hassinen I, Majamaa K. Cardiac
abnormalities in patients with mitochondrial DNA mutation 3243A.G. BMC Car-
diovasc Disord 2002;2:12.
25. Maron BJ, Sato N, Roberts WC, Edwards JE, Chandra RS. Quantitative analysis of
cardiac muscle cell disorganization in the ventricular septum. Comparison of fe-
tuses and infants with and without congenital heart disease and patients with hyper-
trophic cardiomyopathy. Circulation 1979;60:685–696.
26. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left
ventricular collagen network in young patients with hypertrophic cardiomyopathy
and sudden cardiac death. J Am Coll Cardiol 2000;35:36–44.
27. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left
ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.
N Engl J Med 2000;342:1778–1785.
28. Morgan-Hughes JA, Darveniza P, Landon DN, Land JM, Clark JB. A mitochondrial
myopathy with a deficiency of respiratory chain NADH-CoQ reductase activity.
J Neurol Sci 1979;43:27–46.
29. Siler SQ, Neese RA, Christiansen MP, Hellerstein MK. The inhibition of gluconeo-
genesis following alcohol in humans. Am J Physiol 1998;275(5 Pt 1):E897–E907.
30. Shorvon S, Tomson T. Sudden unexpected death in epilepsy. Lancet 2011;378:
2028–2038.
31. Morentin B, Paz Suarez-Mier M, Audicana C, Aguilera B, Manuel Garamendi P,
Elexpe X. Incidence and causes of sudden death in persons less than 36 years of
age. Med Clin (Barc) 2001;116:281–285.
32. Papadakis M, Sharma S, Cox S, Sheppard MN, Panoulas VF, Behr ER. The magnitude
of sudden cardiac death in the young: a death certificate-based review in England
and Wales. Europace 2009;11:1353–1358.
33. Winkel BG, Holst AG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL,
Bundgaard H, Svendsen JH, Haunsø S, Tfelt-Hansen J. Nationwide study of sudden
cardiac death in persons aged 1–35 years. Eur Heart J 2011;32:983–990.
34. CorradoD, Basso C, Rizzoli G, SchiavonM, Thiene G. Does sports activity enhance
the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003;42:
1959–1963.
35. Wisten A, Forsberg H, Krantz P, Messner T. Sudden cardiac death in 15–35-year
olds in Sweden during 1992–99. J Intern Med 2002;252:529–536.
36. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E,
Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM. A novel clinical
risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy
(HCM risk-SCD). Eur Heart J 2014;35:2010–2020.
37. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P,
Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J,
Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH,
Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of
hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management
of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Eur Heart J 2014;35:2733–2779.
38. Hollingsworth KG, GormanGS, Trenell MI, McFarland R, Taylor RW, Turnbull DM,
MacGowan GA, Blamire AM, Chinnery PF. Cardiomyopathy is common in patients
with the mitochondrial DNA m.3243A.Gmutation and correlates with mutation
load. Neuromuscul Disord 2012;22:592–596.
39. Schaefer AM, Bates MGD, Bourke JP, McFarland R, Turnbull DM. Newcastle mito-
chondrial disease guidelines-cardiac involvement in adult mitochondrial disease:
screening and initial management (Updated in 2013). http://www.newcastle-
mitochondria.com/wp-content/uploads/2012/09/Cardiology-Guidelines.pdf (30th
October 2014).
Y.S. Ng et al.Page 8 of 8
by guest on July 20, 2015
D
ow
nloaded from
 
